Parkinson's disease research is reaching a pivotal stage, but funding and clinical trial barriers remain for the successful development of disease-modifying therapies (DMTs). The Czech company Stimvia successfully completed a pilot clinical study of peroneal electrical transcutaneous neuromodulation (eTNM), which confirmed its safety and effectiveness in the treatment of Parkinson's disease symptoms with an emphasis on quality of life[1]. The combination with levodopa could delay the deterioration of the patient's condition without invasive methods such as deep brain stimulation[1]. Up to 80 percent of patients from the pilot study voluntarily decided to continue treatment[1]. This method is already certified according to the MDR and reimbursed by insurance companies in the Czech Republic and abroad for the treatment of overactive bladder, which affects more than 1 million people in the Czech Republic[1]. In 2025, human trials of the CAP-003 gene therapy to correct the GBA gene mutation, which causes the breakdown of brain cells in some patients[3], are underway. The drug Solengepras (CVN-424), in the final phase of testing, could replace surgical stimulation with a pill targeting movement-regulating receptors[3]. The number of cases of Parkinson's disease has increased by 274 percent in 30 years, making it the fastest growing neurodegenerative disease[5].